Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

Lisa Bodei, Marta Cremonesi, Chiara Grana, Paola Rocca, Mirco Bartolomei, Marco Chinol, Giovanni Paganelli

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [ 90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

Original languageEnglish
Pages (from-to)1038-1046
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume31
Issue number7
Publication statusPublished - Jul 2004

Fingerprint

Octreotide
Neuroendocrine Tumors
Radioisotopes
Somatostatin Receptors
Somatostatin
Therapeutics

Keywords

  • Y-DOTATOC
  • Neuroendocrine tumours
  • Receptor radionuclide therapy
  • Somatostatin receptors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

@article{f33431ca5edd48f3ba8e8735cbe39515,
title = "Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours",
abstract = "Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [ 90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.",
keywords = "Y-DOTATOC, Neuroendocrine tumours, Receptor radionuclide therapy, Somatostatin receptors",
author = "Lisa Bodei and Marta Cremonesi and Chiara Grana and Paola Rocca and Mirco Bartolomei and Marco Chinol and Giovanni Paganelli",
year = "2004",
month = "7",
language = "English",
volume = "31",
pages = "1038--1046",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "7",

}

TY - JOUR

T1 - Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

AU - Bodei, Lisa

AU - Cremonesi, Marta

AU - Grana, Chiara

AU - Rocca, Paola

AU - Bartolomei, Mirco

AU - Chinol, Marco

AU - Paganelli, Giovanni

PY - 2004/7

Y1 - 2004/7

N2 - Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [ 90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

AB - Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [ 90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

KW - Y-DOTATOC

KW - Neuroendocrine tumours

KW - Receptor radionuclide therapy

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=3142724702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142724702&partnerID=8YFLogxK

M3 - Article

C2 - 15150675

AN - SCOPUS:3142724702

VL - 31

SP - 1038

EP - 1046

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 7

ER -